In brief: Benitec, XRT, Phylogica, Norwood Abbey
Wednesday, 06 April, 2005
RNAi specialist Benitec (ASX:BLT) has lodged a prospectus with ASIC to raise up to AUD$9.7 million in a rights issue, underwritten by Bell Potter. Capital raised will go towards clinical development and expansion of Benitec's California operations, it said.
Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal in which an unnamed analytical company will incorporate XRT's phase contrast technology in 3D metrology and analysis instruments.
Drug discovery firm Phylogica (ASX:PYC) has named former Peptech and CSL executive Dr Greg Pullen as its chief operating officer. Most recently, Pullen was in charge of licensing at Auckland University's commercialisation entity.
Norwood Abbey (ASX:NAL) has won TGA approval for a key component of its vision correction surgery tool Epi-Lasik.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
